Cyrus Mozayeni takes over from Bertrand Damour as Pheon CEO

25 July 2023

Antibody-drug conjugate (ADC) company Pheon Therapeutics has named Cyrus Mozayeni its new chief executive.

The appointment follows the decision of Bertrand Damour to step down as CEO and coincides with the recent appointment of Jeff Albers as chairman of the board.

"Pheon has a uniquely differentiated and preclinically validated approach to discovering and developing ADC therapeutics"Dr Mozayeni joins Pheon with over more than 20 years of experience in the biotechnology industry. Prior to joining the company, as an entrepreneur-in-residence at Atlas Venture, he co-founded and led Vedere Bio, serving as CEO from inception right through its sale to Novartis (NOVN: VX), in a deal valued at $280 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK